Imigran Nasal Spray

Imigran (sumatriptan) is a well-known prescription medication used for the acute treatment of migraine attacks. Originally developed by the British pharmaceutical company Glaxo (now GlaxoSmithKline), it was the first of the triptan class of drugs to be introduced to the market in the early 1990s. The nasal spray variant shown here is designed for rapid absorption during migraine episodes.

The brand is owned and produced by GSK (GlaxoSmithKline), a global healthcare leader headquartered in London, United Kingdom. While the product is marketed globally, manufacturing often occurs in various specialized pharmaceutical facilities across Europe, including sites in the UK and Italy. In the Nordic markets, such as Sweden, the product is distributed through the regional subsidiary GlaxoSmithKline AB.